Reversal of Multidrug Resistance by Symmetrical Selenoesters in Colon Adenocarcinoma Cells. 2023

Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
Department of Medical Microbiology, Albert Szent-Györgyi Health Center and Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, 6725 Szeged, Hungary.

Recently, selenium containing derivatives have attracted more attention in medicinal chemistry. In the present work, the anticancer activity of symmetrical selenoesters was investigated by studying the reversal of efflux pump-related and apoptosis resistance in sensitive and resistant human colon adenocarcinoma cells expressing the ABCB1 protein. The combined effect of the compounds with doxorubicin was demonstrated with a checkerboard assay. The ABCB1 inhibitory and the apoptosis-inducing effects of the derivatives were measured with flow cytometry. Whole transcriptome sequencing was carried out on Illumina platform upon the treatment of resistant cells with the most potent derivatives. One ketone and three methyl ester selenoesters showed synergistic or weak synergistic interaction with doxorubicin, respectively. Ketone selenoesters were the most potent ABCB1 inhibitors and apoptosis inducers. Nitrile selenoesters could induce moderate early and late apoptotic processes that could be explained by their ABCB1 modulating properties. The transcriptome analysis revealed that symmetrical selenoesters may influence the redox state of the cells and interfere with metastasis formation. It can be assumed that these symmetrical selenocompounds possess toxic, DNA-damaging effects due to the presence of two selenium atoms in the molecule, which may be augmented by the presence of symmetrical groups.

UI MeSH Term Description Entries

Related Publications

Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
June 2015, Anticancer research,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
October 1996, Journal of the National Cancer Institute,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
December 1998, Cancer research,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
May 1997, Yao xue xue bao = Acta pharmaceutica Sinica,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
March 2017, Oncology reports,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
December 2008, Oncology reports,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
March 1996, Cell biochemistry and function,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
January 2009, Molecular medicine reports,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
January 1994, Journal of the National Cancer Institute,
Bálint Rácz, and Annamária Kincses, and Krisztián Laczi, and Gábor Rákhely, and Enrique Domínguez-Álvarez, and Gabriella Spengler
May 2004, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!